---
import Layout from '../../layouts/Layout.astro';
import Header from '../../components/Header.astro';
import Footer from '../../components/Footer.astro';
---

<Layout
  title="Press Release: Cancer Genetic Chain Breakthrough"
  description="Weyland Corporation scientists identify the complete genetic chain responsible for 98% of known cancers, enabling targeted therapies and potential cures for hundreds of cancer types."
  type="article"
>
  <Header />

  <main class="bg-black pt-36">
    <!-- ARTICLE HEADER -->
    <section class="relative py-20 border-b border-[#1a1a1a]">
      <div class="industrial-grid absolute inset-0 opacity-10"></div>

      <div class="relative container mx-auto px-6">
        <div class="max-w-4xl mx-auto">
          <a href="/news" class="inline-flex items-center gap-2 text-[#FFC600] text-xs font-bold uppercase tracking-wider mb-8 hover:text-white transition-colors">
            &larr; BACK TO NEWSROOM
          </a>

          <div class="flex items-center gap-4 mb-6">
            <span class="text-[10px] font-mono text-[#FFC600] tracking-widest bg-[#FFC600]/10 px-3 py-1 clip-corner">HEALTH SCIENCES</span>
            <span class="text-[10px] font-mono text-gray-600 tracking-wider">PRESS RELEASE</span>
          </div>

          <h1 class="text-4xl md:text-5xl lg:text-6xl font-black text-white uppercase leading-none mb-6">
            WEYLAND SCIENTISTS IDENTIFY GENETIC CHAIN FOR <span class="text-[#FFC600]">98% OF KNOWN CANCERS</span>
          </h1>

          <div class="flex flex-wrap items-center gap-6 text-sm text-gray-500 font-mono">
            <span>APRIL 3, 2022</span>
            <span class="text-[#FFC600]">|</span>
            <span>SAN FRANCISCO, CA</span>
            <span class="text-[#FFC600]">|</span>
            <span>FOR IMMEDIATE RELEASE</span>
          </div>
        </div>
      </div>

      <div class="absolute bottom-0 left-0 right-0 hazard-stripes-thin h-1"></div>
    </section>

    <!-- ARTICLE BODY -->
    <section class="relative py-16 bg-black">
      <div class="container mx-auto px-6">
        <div class="max-w-4xl mx-auto">
          <div class="text-gray-300 leading-relaxed space-y-6 text-base">
            <p class="text-lg text-white font-semibold">
              <strong>SAN FRANCISCO --</strong> Weyland Corporation (NASDAQ: WYLD) today announced that researchers at the Corporation's Health Sciences Division have identified and fully mapped the genetic regulatory chain responsible for the initiation and progression of 98% of all known cancer types in humans. The discovery, published today in the journal <em>Nature</em>, represents the single most significant advance in oncological science since the identification of oncogenes in the 1970s and is expected to fundamentally transform the prevention, diagnosis, and treatment of cancer worldwide.
            </p>

            <p>
              The research team, led by Dr. Sarah Okonkwo, Director of Genomic Medicine at Weyland Corporation, identified a previously unknown cascade of 47 interconnected gene regulatory sequences that collectively govern the cellular mechanisms responsible for uncontrolled cell growth. The cascade, designated the Weyland Oncogenic Regulatory Network (WORN), operates across virtually all human tissue types and, when disrupted, initiates the malignant processes that manifest as cancer.
            </p>

            <p>
              "For decades, cancer research treated each cancer type as a separate disease," said Dr. Okonkwo. "Our work demonstrates that the vast majority of cancers share a common regulatory architecture. They are not hundreds of different diseases. They are hundreds of different expressions of the same underlying genetic dysfunction. And now that we understand that dysfunction, we can address it directly."
            </p>

            <h2 class="text-2xl font-black text-white uppercase mt-12 mb-4">SCOPE OF THE DISCOVERY</h2>
            <div class="h-px w-24 bg-[#FFC600] mb-6"></div>

            <!-- RESEARCH DATA -->
            <div class="my-8 corp-card p-8">
              <h3 class="text-lg font-black text-[#FFC600] uppercase mb-6">RESEARCH SUMMARY</h3>
              <div class="grid md:grid-cols-3 gap-8 text-center">
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">98%</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">OF KNOWN CANCERS COVERED</div>
                </div>
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">47</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">REGULATORY GENE SEQUENCES</div>
                </div>
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">6 YR</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">RESEARCH DURATION</div>
                </div>
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">$7.1B</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">TOTAL RESEARCH INVESTMENT</div>
                </div>
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">2,400</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">RESEARCHERS INVOLVED</div>
                </div>
                <div>
                  <div class="text-3xl font-black text-[#FFC600]">14.2M</div>
                  <div class="text-xs text-gray-500 font-mono uppercase mt-2">GENOMIC SAMPLES ANALYZED</div>
                </div>
              </div>
            </div>

            <p>
              The research analyzed 14.2 million genomic samples from cancer patients across 193 countries, representing the largest genomic dataset ever assembled for a single study. The computational analysis was performed on Weyland Corporation's proprietary quantum computing platform, which processed data volumes that would have required an estimated 4,000 years of conventional supercomputer time.
            </p>

            <h2 class="text-2xl font-black text-white uppercase mt-12 mb-4">THERAPEUTIC IMPLICATIONS</h2>
            <div class="h-px w-24 bg-[#FFC600] mb-6"></div>

            <p>
              The identification of the WORN cascade enables the development of targeted therapies that address cancer at its genetic root rather than treating symptoms at the tissue level. Weyland Corporation's Health Sciences Division has already initiated development of gene-editing therapeutics designed to repair or neutralize disrupted elements of the WORN cascade. Preliminary laboratory results indicate that targeted intervention at key nodes in the cascade can halt malignant cell growth in cultured human tissue samples with an efficacy rate exceeding 94%.
            </p>

            <p>
              "We are not talking about incremental improvement. We are talking about the potential to cure cancer," said Peter Weyland, Founder and CEO of Weyland Corporation. "Not to manage it. Not to slow it down. To cure it. The science tells us this is achievable. We will commit whatever resources are necessary to make it real."
            </p>

            <p>
              Weyland Corporation has committed an additional $16 billion over the next five years to accelerate the development of WORN-targeted therapeutics, with Phase I clinical trials anticipated to begin in 2024. The Corporation has also pledged to license the underlying research to academic and nonprofit institutions at zero cost, ensuring global access to the foundational science.
            </p>

            <p>
              Weyland Corporation shares rose 11.2% following the announcement. The World Health Organization issued a statement describing the discovery as "a turning point in the history of medicine."
            </p>

            <!-- BOILERPLATE -->
            <div class="mt-16 pt-8 border-t border-[#1a1a1a]">
              <h3 class="text-sm font-black text-[#FFC600] uppercase tracking-wider mb-4">ABOUT WEYLAND CORPORATION</h3>
              <p class="text-sm text-gray-500 leading-relaxed">
                Weyland Corporation is a multinational technology company and the global leader in health sciences, atmospheric science, and advanced engineering. Founded in 2012 by Peter Weyland, the Corporation employs more than 62,000 people across 22 countries. Weyland Corporation is publicly traded on NASDAQ under the symbol WYLD.
              </p>

              <h3 class="text-sm font-black text-[#FFC600] uppercase tracking-wider mb-4 mt-8">FORWARD-LOOKING STATEMENTS</h3>
              <p class="text-sm text-gray-500 leading-relaxed">
                This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected. Weyland Corporation undertakes no obligation to update forward-looking statements.
              </p>

              <h3 class="text-sm font-black text-[#FFC600] uppercase tracking-wider mb-4 mt-8">MEDIA CONTACT</h3>
              <p class="text-sm text-gray-500">
                Corporate Communications<br/>
                media@weylandcorp.com<br/>
                +1-800-555-WYLD
              </p>
            </div>
          </div>
        </div>
      </div>
    </section>
  </main>

  <Footer />
</Layout>

<style>
  .clip-corner {
    clip-path: polygon(8px 0, 100% 0, 100% calc(100% - 8px), calc(100% - 8px) 100%, 0 100%, 0 8px);
  }
</style>
